Researchers have also known about and documented periodic
shifts over cycles of 21,000 years, 41,000 years and 100,000 years, all of them also driven by astronomical change.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated
shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant
cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products
over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
I emphasize the phrase «from current price levels,» as a significant retreat in valuations is likely to dramatically
shift this profile, as it has
over the completion of every market
cycle in history.
I have no question that these conditions will emerge
over the completion of the current market
cycle, and - despite the truncated bullish
shift and awkward transition that followed my 2009 stress - testing decision - there is not a single market
cycle in 30 years as a professional investor where those same conditions did not provoke me to adopt a constructive outlook.
Additionally, the U.S. economy has dramatically changed
over the past several years, with structural factors (largely the result of technological innovation and
shifting demographic trends) influencing it in a manner that makes comparisons to past rate hiking
cycles less relevant.
If market internals improve, we'll take a signal that investors have
shifted back to risk - seeking, and that would ease our near - term concerns, but wouldn't materially change our expectations for a market loss on the order of 50 % or more
over the completion of the current
cycle.
In addition to the long - term growth trend, there have been structural
shifts in the semiconductor industry
over the past few years that should make
cycles less volatile going forward.
But a serious analysis of survey data
over time provides little evidence that this fall's election
cycle substantially
shifted public opinion in favor of legal abortion.
Over the past ninety years or so, the American debate about the national interest and the national purpose» the debate about morality and foreign policy» has careened through at least ten
cycles, resulting in numerous, and sometimes jarring,
shifts in the nation's approach to the world.
[Spin
Cycle] Capitalizing Callaghan
Shifts Into Overdrive [Newsday] Hevesi's Security Detail Twice As Large As Spitzer's [AP] Alan Overdrive [NYP] Aide's «Squad» Car Ride [NYDN] Hevesi Smooches Up Pol Pal [NYP] Thanks to Hevesi, Democrats Face Political Tightrope [NYS] Pataki Picks Ex-Prosecutor to Weigh In on Hevesi Case [NYT] Hevesi: I'd Quit
Over Ax [NYP]
As the major areas of contention become clear, some remain from recent years, while others are new, and questions loom
over the city budget
cycle due to uncertainty in Washington, D.C., state funding
shifts being proposed by Gov. Andrew Cuomo, and a slowing city economy.
Fluctuations at the core subtly
shift the planet's rotation
over a six - year
cycle.
Processes that have historically altered the face of the planet, like
cycles in the Earth's orbit around the Sun or
shifts in continental tectonic plates, occur
over tens of thousands to millions of years.
The sun's activity
shifts over the course of its 11 - year
cycle, with sun spot numbers, radiation levels, and ejected material changing
over time.
In proper proportion, these hormones are like the two sides of a seesaw,
shifting rhythmically back and forth
over the course of the menstrual
cycle.
Again, it's still early in the life
cycle of both tablets and e-readers, and so we're going to see a lot of
shifts over time as more groups find utility in these products.
It is rough for anyone relying on ratings during the bust of the
cycle, because the philosophy
shifts from «ratings are made
over a full credit
cycle» to «ratings should last until lunchtime, maybe, uh, look the stock price is down 5 %, post a downgrade.»
Given how much yelling takes place on the Internet, talk radio, and elsewhere
over short - term cool and hot spells in relation to global warming, I wanted to find out whether anyone had generated a decent decades - long graph of global temperature trends accounting for, and erasing, the short - term up - and - down flickers from the cyclical
shift in the tropical Pacific Ocean known as the El Niño — Southern Oscillation, or ENSO,
cycle.
SCL» & SCL» -LRB--1 / 4
cycle shift from SCL») do not have stationary periods
over the 1749 + sunspot record, but they've recently hit ~ 60 years for 2 consecutive
cycles.
This analysis is probably floored, and the economics probably a little better because power prices will rise
over time and batteries partially
cycle from moment to moment and so can actually
shift more power but this is of little economic benefit when net metering is available (giving near retail rates to exported power) and so the fact remains batteries are still uneconomic by a factor of 300 % even with the SGIP.
Those who invoke the solar
cycle, to which there is no global temperature correlation even if one allows for phase
shifts, or who cite possible increases in solar flux, of which observations show none
over this warming epoch, are especially off the mark.
So there's been NO ocean
cycle influence whatsoever
over this period, the Great Pacific Climate
Shift of 1976/77 had no impact at all on global temperatures.
The predominance of landmasses in the northern hemisphere causes glaciations to predominate
over interglacials by about 9 to 1 with a full
cycle every 100, 000 years helped along by the orbital changes of the Milankovitch
cycles that affect the pattern of insolation on those
shifting cloud masses.
Regonda et al 2005: «Seasonal
Cycle Shifts in Hydroclimatology
over the Western United States» http://civil.colorado.edu/~balajir/my-papers/regonda-etal-jclim.pdf
While in - house growth has
cycled up and down
over the years as is typical of most industries» pendulum swings between insourcing and outsourcing, our most recent growth surge (
over the last 7 - 10 years) was uncommonly large and fast - paced, with the result that some law departments suddenly find themselves too expensive for the work they currently perform (based on the market value of the work) and others may find themselves too ungainly to be agile in responding to market service offerings (where they previously could have insourced or outsourced work based on emerging and
shifting needs).
The position of the Arctic Circle is not fixed and,
over the course of the slow and cyclical 40,000 year
shifting of the Earth's axial tilt, it fluctuates by a margin of two degrees — at the point of the
cycle we're now in, it is drifting northwards at a rate of 49 feet (15 meters) per year.
REIT analyst Steve Manaker says he has seen REITs
shifting focus among management teams from short - term goals to sustained growth
over market
cycles.